Key result
Metformin links to short-term hemoglobin decreases but shows no long-term difference versus DPP-4 inhibitors.
Why the study?
Metformin is linked to micronutrient deficiencies that may contribute to anemia risk, but real-world evidence on hemoglobin trajectories following metformin initiation remains limited.
Does metformin initiation reduce hemoglobin levels compared with dipeptidyl peptidase-4 inhibitors in Japanese patients with type 2 diabetes?
Cohort (n=364)
No
Does metformin initiation reduce hemoglobin levels compared with dipeptidyl peptidase-4 inhibitors in Japanese patients with type 2 diabetes?
Metformin initiation is associated with a short-term decrease in hemoglobin levels, but does not cause an excess long-term decline compared to DPP-4 inhibitors.
Answers are grounded in this paper and cite their sources.
Short-term hemoglobin decline after metformin start warrants monitoring; observational data leave open causality and long-term anemia risk.
Background Metformin is associated with vitamin B12 deficiency, and we recently reported latent iron and copper deficiency among metformin users, suggesting a potential contribution to anemia risk. However, real-world evidence on hemoglobin trajectories after metformin initiation remains limited. We evaluated short- and long-term hemoglobin changes after metformin initiation compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in Japanese patients with type 2 diabetes. Methods This single-center retrospective cohort study used electronic medical record data from Kobe University Hospital from January 2014 to June 2025. Short-term hemoglobin changes were defined as changes from Day 0 to Day 180, and long-term trajectories were evaluated from Day 0 to Day 1,826 (five years). Patients initiating metformin or a DPP-4 inhibitor were selected using predefined eligibility and exclusion criteria and matched by propensity scores. Hemoglobin changes over 180 days and up to five years were analyzed using multiple regression and mixed-effects models. Results The short-term cohort included 72 matched pairs, and the long-term cohort included 182 matched pairs. Hemoglobin decreased from 14.74 ± 0.22 to 14.39 ± 0.23 g/dL (mean ± SEM) from Day 0 to Day 180 in the metformin group, whereas no significant change was observed in the DPP-4 inhibitor group. Pre-initiation hemoglobin change, but not metformin dose, was independently associated with subsequent hemoglobin change. Over five years, annual hemoglobin slopes did not differ significantly between groups (-0.0572 vs. -0.0725 g/dL/year, p = 0.31). Older patients showed more negative annual hemoglobin slopes in both groups. Conclusions Metformin initiation was associated with a short-term hemoglobin decrease, whereas excess long-term decline was not observed in this cohort. Long-term changes were modest and age-related, supporting continued monitoring in older patients.
No takes yet. Share an insight, caveat, or question.
Morita et al. (2026) conducted a cohort in Type 2 diabetes (n=364). Metformin vs. Dipeptidyl peptidase-4 (DPP-4) inhibitors was evaluated on Annual rate of hemoglobin change over five years (g/dL/year) (p=0.31). Metformin initiation was associated with a short-term hemoglobin decrease, but did not result in a significant difference in annual hemoglobin decline over five years compared with DPP-4 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: